Sugar Restriction in Infancy Tied to Lower Cancer Risk; Melanoma Vaccine Shows Promise
A study found that people with restricted sugar exposure during their first two years had a lower adult cancer risk, while another linked antioxidant-rich diets to reduced cervical cancer risk. The FDA declined approval for a dasatinib formulation due to manufacturing issues, and a phase III trial showed that adding a cancer vaccine to pembrolizumab improved outcomes in resected melanoma. Additional findings included fewer than 15% of eligible lung cancer patients discussing screening with doctors, and centenarians having an abundance of cancer-fighting immune cells.
The sugar restriction study, published in the American Journal of Clinical Nutrition, suggests that limiting sugar intake during the first two years of life may have long-term protective effects against adult cancer. Separately, a phase III trial combining the intismeran autogene vaccine with pembrolizumab improved recurrence-free and distant metastasis-free survival in resected melanoma patients. Another notable development involves a sugar-based "antifreeze" technique for preserving CAR-T cells, which could broaden access to this therapy. Additionally, research on centenarians indicates they possess an unusually high number of cancer-fighting immune cells, offering clues for future interventions.
This collection of findings could reshape cancer prevention and treatment strategies, particularly if early-life dietary interventions prove broadly effective. The melanoma vaccine's success may expand immunotherapy options, while the CAR-T preservation method could lower costs and increase availability. However, low lung cancer screening rates highlight persistent gaps in early detection, meaning many eligible patients still miss opportunities for timely intervention. These advances may benefit some populations more than others, depending on access to care and lifestyle factors.